<DOC>
	<DOCNO>NCT01275859</DOCNO>
	<brief_summary>Cross-talk epidermal growth factor ER occur multiple level seem play crucial role breast cancer progression endocrine resistance.Combined HER1/HER2-targeted therapy aromatase inhibitor ER-positive HER-2 positive postmenopausal breast cancer might enhance response block emergence endocrine resistant tumor .</brief_summary>
	<brief_title>Neoadjuvant Combined Endocrine HER2 Target Therapy Postmenopausal Women With ER Her2 Positive Breast Cancer</brief_title>
	<detailed_description>1 . To evaluate efficacy neoadjuvant combination therapy letrozole lapatinib postmenopausal patient ER-positive HER2-positive breast cancer . 2 . To assess marker predictive treatment response outcome setting .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Written inform consent Female patient Histologically confirm invasive breast cancer Primary tumor great 2cm diameter , measure sonography N03 ( N resectable ) evidence distant metastasis ( M ) ( isolated supraclavicular node involvement allow ) ER positive ( intermediate strong positive ) HER2 positive ( IHC3+ FISH positive case IHC 2+ ) No evidence metastasis ( M0 ) No prior hormonal , chemotherapy radiotherapy allow No breast operation biopsy make diagnosis allow Postmenopausal woman ECOG Performance Status 0 1 Postmenopausal , define following : At least 55 year age Under 55 year age amenorrheic least 12 month OR folliclestimulating hormone ( FSH ) value ≥ 30 IU/L estradiol level ≤ 20 IU/L Prior bilateral oophorectomy prior radiation castration amenorrhea least 6 month Adequate hematopoietic , renal , hepatic function : Patients receive hormonal , chemotherapy radiotherapy breast cancer Patients underwent surgery breast cancer Patients bilateral invasive breast cancer Patients inflammatory breast cancer ( T4d ) Patients without primary tumor ( T0 ) Inability perform [ 18F ] FES PET image due physical inability , claustrophobia , mental illness . ER poor disease define locally ( e.g : Allred score 13 , Hscore &lt; 100 ) Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer Chronic daily treatment aspirin ( &gt; 325mg/day ) clopidogrel ( &gt; 75mg/day ) Chronic daily treatment corticosteroid ( dose &gt; 10mg /day ethylprednisolone equivalent ) Clinically significant cardiovascular disease : CVA/stroke ( &lt; 6month prior enroll ) , MI ( &lt; 6month prior enroll ) , unstable angina , NYHA Grade II great congestive heart failure , serious cardiac arrhythmia require medication . Hormone replacement therapy within 4 week start treatment Known hypersensitivity study drug include ditosylate monohydrate salt Pregnant nursing mother ( applicable )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Neoadjuvant</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>